Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: BNTX stock price vs FDS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FDS's multiple
Needs FDS P/S.
Implied fair value · at BNTX's multiple
Needs BNTX P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BNTX FY 2025 (ended Dec 31, 2025) · FDS FY 2025 (ended Aug 31, 2025). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
BioNTech SE · implied price per share
Bear
-$6.81
Base
-$8.01
Bull
-$9.21
FACTSET RESEARCH SYSTEMS INC. · implied price per share
Bear
$170.12
Base
$200.14
Bull
$230.17
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
0.68x
Net debt / EBITDA
Leverage against operating earnings
4.45x
1.18x
Cash and equivalents
Liquid reserves on the balance sheet
$7.68B
$355.10M
Total debt
Interest-bearing obligations outstanding
$2.68B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
BNTX vs MRNA
GILEAD SCIENCES, INC.
BNTX vs GILD
AMGEN INC
BNTX vs AMGN
REGENERON PHARMACEUTICALS, INC.
BNTX vs REGN
INCYTE CORP
BNTX vs INCY
VERTEX PHARMACEUTICALS INC / MA
BNTX vs VRTX
MOODYS CORP /DE/
BNTX vs MCO
MARKETAXESS HOLDINGS INC
BNTX vs MKTX
GLOBAL PAYMENTS INC
BNTX vs GPN
FISERV INC
BNTX vs FI
JACK HENRY & ASSOCIATES INC
BNTX vs JKHY
PayPal Holdings, Inc.
BNTX vs PYPL
$1.49B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe BNTX can rapidly improve gross margin and reverse its negative earnings profile, then consider holding; otherwise, the data supports reducing exposure because BNTX trades at a premium P/S multiple to FDS despite much weaker profitability and a very weak Piotroski score.
BNTX is priced at $92.33 versus an implied price of $49.02 from the P/S comparison, implying 46.9% downside. The gap is especially notable because BNTX trades at a richer P/S multiple than FDS even though its margins and earnings profile are far weaker.
Supporting Metrics
